Skip to main content
. 2018 Feb 1;7(5):e1424674. doi: 10.1080/2162402X.2018.1424674

Figure 2.

Figure 2.

Serum levels of ipilimumab. Serum ipilimumab (s-ipilimumab) levels in 31 patients with metastatic melanoma were measured at baseline, and before the 2nd and 4th infusions of ipilimumab. Seven samples drawn before the 2nd infusion were excluded from analysis due to high background noise (n = 3) or a too long or short interval since the previous infusion (n = 4). Eleven samples drawn before the 4th infusion were unavailable for analysis because they were missing (n = 6), or excluded due to high background signal (n = 2) or a too long or short interval since the previous infusion (n = 3).